Kooperativer Bibliotheksverbund

UID:

Format: 1 online resource (xx, 554 pages) : , digital, PDF file(s).

ISBN: 1-108-98515-7 , 1-108-98329-4 , 1-108-97575-5

Series Statement: Cambridge medicine

Content: Alzheimer's Disease (AD) is a growing global public health challenge. The development of new therapies is urgently needed, and a complex ecosystem of organizations has grown to facilitate AD drug discovery and development. Masterfully collating information on the drug development ecosystem, this book emphasizes the contributions of each aspect in the pipeline with a uniform approach to chapters, enabling readers to access relevant information quickly. Topics covered include the use of non-clinical laboratory studies, biomarker development, artificial intelligence, design and management of clinical trials, and funding and financing models. Also discussed is the critical role of advocacy fundraising for drug development. With the approval of aducanumab, the function of the ecosystem has become apparent. This is a definitive overview of how the ecosystem works in transferring an AD drug from its discovery in the laboratory through clinical trial testing to regulatory review and eventual marketing.

Note: Title from publisher's bibliographic system (viewed on 07 Mar 2022). , Cover -- Half-title page -- Title page -- Dedication page -- Copyright page -- Contents -- List of Contributors -- Foreword -- Acknowledgments -- Section 1: Advancing Alzheimer's Disease Therapies in a Collaborative Science Ecosystem -- 1 Alzheimer's Disease Drug Development: A Research and Development Ecosystem -- 2 Drug Development for Alzheimer's Disease: An Historical Perspective -- 3 Alzheimer's Disease Drug Discovery in Academia: From High-Throughput Screening to In Vivo Testing -- 4 The Harrington Discovery Institute and Alzheimer's Disease Drug Development -- 5 Repurposed Agents in Alzheimer's Disease Drug Development -- 6 Artificial Intelligence in Alzheimer's Drug Discovery -- Section 2: Non-clinical Assessment of Alzheimer's Disease Candidate Drugs -- 7 Role of Animal Models in Alzheimer's Disease Drug Development -- 8 Use of Induced Pluripotent Stem Cell-Derived Neuronal Disease Models from Patients with Familial Early-Onset Alzheimer's Disease in Drug Discovery -- 9 Preclinical Longitudinal In Vivo Biomarker Platform for Alzheimer's Disease Drug Discovery -- 10 Biobanking and Biomarkers in the Alzheimer's Disease Drug-Development Ecosystem -- Section 3: Alzheimer's Disease Clinical Trials -- 11 Phase 1 Trials in Alzheimer's Disease Drug Development -- 12 The Importance of Phase 2 in Drug Development for Alzheimer's Disease -- 13 Alzheimer's Disease Drug Development in Pharmaceutical Companies -- 14 Trial Site Infrastructure and Management: Importance to Alzheimer's Disease Drug Development -- 15 ATRI and ACTC: Academic Programs to Accelerate Alzheimer's Disease Drug Development -- 16 The European Prevention of Alzheimer's Disease Program: A Public-Private Partnership to Facilitate the Secondary Prevention of Alzheimer's Disease Dementia. , 17 The Global Alzheimer's Platform Foundation®: Delivering New Medicines Faster by Accelerating Clinical Trials -- 18 Clinical Trial Development in Frontotemporal Lobar Degeneration -- 19 Statistical Considerations in the Design and Analysis of Alzheimer's Disease Clinical Trials -- 20 Alzheimer's Disease Trial Recruitment and Diversifying Trial Populations -- 21 The Role of Online Registries in Accelerating Alzheimer's Disease Drug Development -- 22 Data Safety Monitoring Boards in Alzheimer's Disease Trials -- 23 Globalization of Alzheimer's Disease Clinical Trials -- 24 The Use and Development of Clinical Measures of Alzheimer's Disease Trials -- 25 Tele-Trials, Remote Monitoring, and Trial Technology for Alzheimer's Disease Clinical Trials -- 26 Expanded Access and Compassionate Use in Alzheimer's Disease Drug Development -- 27 The Role of the Contract Research Organization in Alzheimer's Disease: The Vital Link in the Clinical Drug-Development Program -- 28 The Role of Regulatory Agencies in Alzheimer's Disease Drug Development -- 29 Alzheimer's Disease Clinical Trial Study Partners -- 30 From Trials to Practice: Are We Ready for a Disease-Modifying Treatment? -- 31 Best Practices for Clinical Trials during COVID-19 -- Section 4: Imaging and Biomarker Development in Alzheimer's Disease Drug Discovery -- 32 Development of Fluid Biomarkers for Alzheimer's Disease -- 33 Brain Imaging for Alzheimer's Disease Clinical Trials -- 34 Sharing of Alzheimer's Disease Research Data in the Global Alzheimer's Association Interactive Network -- 35 Pharmacogenetics in Alzheimer's Disease Drug Discovery and Personalized Treatment -- 36 The Role of Electroencephalography in Alzheimer's Disease Drug Development -- Section 5: Academic Drug-Development Programs -- 37 Institutional Review Boards and Oversight of Alzheimer's Disease Trials. , 38 SPARKing Drug Development for Alzheimer's Disease in Academia -- 39 The Role of Professional Associations and Patient Advocacy in Advancing Alzheimer's Disease Drug Development -- Section 6: Public-Private Partnerships in Alzheimer's Disease Drug Development -- 40 Alzheimer's Disease Neuroimaging Initiative -- Section 7: Funding and Financing Alzheimer's Disease Drug Development -- 41 Financing Alzheimer's Disease Drug Development -- 42 Valley of Death and the Role of Venture Philanthropy in Alzheimer's Disease Drug Development -- 43 Alzheimer's Association Funding and Policy for Alzheimer's Disease Drug Development -- 44 The Role of Philanthropy in Alzheimer's Disease Therapeutic Development -- 45 National Institute on Aging's Alzheimer's Disease Translational Research Program: Diversifying the Drug-Development Pipeline for the Treatment and Prevention of Alzheimer's Disease and Related Dementias -- 46 Alzheimer's Disease Drug Discovery and the Evolution of Start-Up Biotechnology Companies: Cognition Therapeutics, Inc. as a Case Study -- 47 Introduction to Venture Capital in Alzheimer's Disease Drug Development -- 48 Federal Small Business Support for Small Businesses Pursuing Alzheimer's Disease Drug Development -- Index.

Additional Edition: ISBN 1-108-83866-9

Language: English

URL: lizenzpflichtig

URL: https://doi.org/10.1017/9781108975759

UID:

Format: 1 online resource (1151 p.)

Edition: 7th ed.

ISBN: 1-4377-2075-7

Series Statement: Expert consult. Online and print

Content: Popular with generations of practitioners, Brocklehurst's Textbook of Geriatric Medicine and Gerontology has been the definitive reference of choice in the field of geriatric care. The new 7th Edition, by Howard M. Fillit, MD, Kenneth Rockwood, MD, and Kenneth Woodhouse, carries on this tradition with an increased clinical focus and updated coverage to help you meet the unique challenges posed by this growing patient population. Consistent discussions of clinical manifestations, diagnosis, prevention, treatment, and more make reference quick and easy, while over 255 illustrations compliment

Note: Description based upon print version of record. , FrontCover; BROCKLEHURST'S TEXTBOOK OF GERIATRIC MEDICINE ANDGERONTOLOGY; Copyright; Contributors; Acknowledgments; Contents; Color Plates; Section I Gerontology; CHAPTER 1Introduction: Aging, Frailty, and Geriatric Medicine; CHAPTER 2The Epidemiology of Aging; INTRODUCTION; QUALITY OF LIFE AND DISABILITY; CONCLUSIONS; CHAPTER 3The Future of Old Age; HISTORICAL DETERMINANTS OF THE FUTURE HEALTH OF THE ELDERLY; CURRENT AND FUTURE BIOMEDICAL INPUTS TO AGING; THE FUTURE OF AGING; CHAPTER 4Evolution Theory and the Mechanismsof Aging; EVOLUTION OF AGING; GENETICS OF LIFE SPAN , TESTS OF THE EVOLUTIONARY THEORIESCONCLUSIONS; CHAPTER 5Methodological Problems of Research in Older People; INTRODUCTION; CHAPTER 6Biology of Aging; INTRODUCTION; THE INSULIN-SIGNALING PATHWAY AND LONGEVITY REGULATION; CELL PROLIFERATION, TELOMERASE, AND TELOMERE FUNCTION; CELL DEATH AND CELL REPLACEMENT -A CRITICAL ROLE FOR STEM CELLS?; PROGEROID SYNDROMES AND NORMAL AGING; PROTEIN DAMAGE AND SARCOPENIA-DOES PROTEIN OXIDATIVE DAMAGE PLAY A CAUSAL ROLE?; WHY INVEST IN BASIC AGING RESEARCH?-THE LONGEVITY DIVIDEND; CHAPTER 7Genetic Mechanisms of Aging; INTRODUCTION , MITOCHONDRIAL GENETICS, OXIDATIVE STRESS, AND AGINGCHROMOSOMAL GENE MUTATIONS AND AGING; DESTRUCTIVE AGENTS IN CELLULAR AGING; CHAPTER 8Cellular Mechanisms of Aging; DESTRUCTIVE AGENTS IN CELLULAR AGING; CELL SENESCENCE; PROTEIN SYNTHESIS AND DEGRADATION; SIGNALING PATHWAYS; EXTRACELLULAR MATRIX; CONCLUSION; CHAPTER 9Physiology of Aging; PHYSIOLOGIC DETERIORATION AND THE AGING PHENOTYPE; INTERSPECIES AND INTRASPECIES VARIATION IN AGE-ASSOCIATED PHYSIOLOGIC DETERIORATION; AGE CHANGES IN THE PHYSIOLOGY OF SPECIFIC ORGANS AND ORGAN SYSTEMS; AGE CHANGES IN ORGANISMIC FUNCTION , SUMMARY AND CONCLUSIONSCHAPTER 10A Clinico-Mathematical Model of Aging; INTRODUCTION; THE PHENOTYPIC DEFINITION OF FRAILTY; DEVELOPMENT OF A FRAILTY INDEX BASED ON COMPREHENSIVE GERIATRIC ASSESSMENT; CHAPTER 11 The Premature Aging Syndrome Hutchinson-Gilford Progeria: Insights Into Normal Aging; INTRODUCTION; THE PROPERTIES OF CONNECTIVE TISSUES; CHAPTER 12Connective Tissues and Aging; THE PROPERTIES OF CONNECTIVE TISSUES; BIOSYNTHESIS; DEGRADATION OF CONNECTIVE TISSUE COMPONENTS; AGING AND THE PROPERTIES OF CONNECTIVE TISSUES; SUMMARY , CHAPTR 13 Clinical Immunology: Immune Senescence and the Acquired Immune Deficiency of AgingCHANGES IN THE HUMAN IMMUNE SYSTEM WITH AGING; CLINICAL CONSEQUENCES OF IMMUNE SENESCENCE; SECONDARY CAUSES OF ACQUIRED IMMUNODEFICIENCY IN OLD AGE; CONCLUSIONS; CHAPTER 14Effects of Aging on the Cardiovascular System; AGING-ASSOCIATED CHANGES IN VASCULAR STRUCTURE; ENDOTHELIAL FUNCTION IN AGING; AGING-ASSOCIATED CHANGES IN VASCULAR STRUCTURE; ENDOTHELIAL FUNCTION IN AGING; ARTERIAL STIFFNESS IN AGING ARTERIES; ARTERIAL STIFFNESS IN AGING ARTERIES , EFFECT OF THE AGING PROCESS ON THE STRUCTURE OF THE HEART , English

Additional Edition: ISBN 1-4160-6231-9

Language: English

URL: Volltext  (URL des Erstveröffentlichers)

UID:

Format: XX, 1683 S , Ill., graph. Darst , 29cm

Edition: 5. ed

ISBN: 0443053707

Note: Previous ed. published as: Textbook of geriatric medicine and gerontology. 1992 , Literaturangaben

Language: English

Keywords: Geriatrie ; Gerontologie

UID:

Format: Lit.; Schaub.; Tab.; Übers.

ISSN: 0016-867X

Note: Band: 53; Heft: 4; Seiten: 76-89

In: Geriatrics, Cleveland, Ohio : Advanstar Communications, 1946, 53(1998), 4, Seite 76-89, 0016-867X

In: volume:53

In: year:1998

In: number:4

In: pages:76-89

Language: English

UID:

Format: Tab.; Lit.

ISSN: 0002-8614

Note: Band: 31; Heft: 5; Seiten: 278-281

In: American Geriatrics Society, Journal of the American Geriatrics Society, Malden, Mass. : Wiley-Blackwell, 1953, 31(1983), 5, Seite 278-281, 0002-8614

In: volume:31

In: year:1983

In: number:5

In: pages:278-281

Language: English

UID:

Format: Lit.

ISSN: 0016-867X

Note: Band: 46; Heft: 7; Seiten: 70-72

In: Geriatrics, Cleveland, Ohio : Advanstar Communications, 1946, 46(1991), 7, Seite 70-72, 0016-867X

In: volume:46

In: year:1991

In: number:7

In: pages:70-72

Language: English

UID:

Format: Tab.; Lit.

ISSN: 0016-867X

Note: Band: 44; Heft: 7; Seiten: 65-70

In: Geriatrics, Cleveland, Ohio : Advanstar Communications, 1946, 44(1989), 7, Seite 65-70, 0016-867X

In: volume:44

In: year:1989

In: number:7

In: pages:65-70

Language: English

UID:

Format: Übers.; Lit.

ISSN: 0016-867X

Note: Band: 50; Heft: 3; Seiten: 33-39

In: Geriatrics, Cleveland, Ohio : Advanstar Communications, 1946, 50(1995), 3, Seite 33-39, 0016-867X

In: volume:50

In: year:1995

In: number:3

In: pages:33-39

Language: English

UID:

Format: Lit.; Tab.

ISSN: 0016-867X

Note: Band: 49; Heft: 1; Seiten: 27-35

In: Geriatrics, Cleveland, Ohio : Advanstar Communications, 1946, 49(1994), 1, Seite 27-35, 0016-867X

In: volume:49

In: year:1994

In: number:1

In: pages:27-35

Language: English

UID:

ISBN: 083421363X

Note: Seiten: 135-144

In: Healthy aging, Gaithersburg, Md : Aspen Publishers, 1999, (1999), Seite 135-144, 083421363X

In: year:1999

In: pages:135-144

Language: English